Medicenna Therapeutics Corp
MDNA
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.93M
Close$
$0.36
128.9% upside
Current Fair Value
128.9% upsideUndervalued by 128.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.93 Million |
|---|---|
| Enterprise Value | $-11,058,917.00 |
| Dividend Yield | $- (NaN%) |
| Earnings per Share | $0.02 |
| Beta | 0.77 |
| Outstanding Shares | 69,637,469 |
Return
| Return on Equity | -60.05% |
|---|---|
| Return on Assets | -50.73% |
| Return on Invested Capital | -93.91% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 1.46 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Medicenna Therapeutics Corp
20 employees
CEO: Fahar Merchant Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It dev...